Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpicilib-Enhanced Adjuvant Endocrine Therapy in ER+/HER2- Early Breast Cancer
NCT06637150Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalpiciclib in breast cancer, sponsored by Fudan University. Started Jan 2025; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06637150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637150.